Search companies

Live

SYNTARA LIMITED (ASX: SNT)

Health care · News and insights

Price unavailable

Latest SNT announcements

Syntara Pauses SNT-9465 Trial Recruitment Over Skin Irritation

2026-11-10 · Health care

SNT: $0.016 -15.79% · MC: $28M

Syntara has paused recruitment in its Phase 1b SNT-9465 scar study after reports of mild to moderate skin irritation among some participants. The company will review unblinded data before deciding whether to resume recruitment or discontinue the study, with the review expected to finish this quarter.

Updated 2026-11-10 09:53
Share
SourcesSyntara Pauses SNT-9465 Phase 1b Recruitment
Comments

Syntara Reports Parkinson’s Trial Signals as Pipeline Advances

2026-10-30 · Health care

SNT: $0.019 -2.63% · MC: $28M

Syntara reported preliminary Phase 2 results for SNT-4728 showing reduced inflammation in a Parkinson’s-related brain region, with additional post-quarter results indicating improved clinician-assessed motor signs versus placebo 12 weeks after treatment ended. Its AZALOX study advanced to the final Phase 1b dose cohort, while the SNT-9465 scar study expanded after quarter-end; top-line results are expected in early 2027. The company also received approximately $5 million in R&D tax incentives.

Updated 2026-10-30 13:28
Share
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments